4 news items
Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC)
GTHX
28 May 24
/tolerability, as well as objective response rate (ORR), clinical benefit rate (CBR; confirmed complete response, partial response, or stable disease lasting
Evaluating G1 Therapeutics: Insights From 5 Financial Analysts
GTHX
1 May 24
their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to G1 Therapeutics
Breaking Down G1 Therapeutics: 5 Analysts Share Their Views
GTHX
12 Apr 24
they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to G1 Therapeutics. This offers insight
Biotech Innovations Paving the Way in Breast Cancer Fight
AZN
GILD
GTHX
11 Apr 24
response rate, a 50% improvement in median progression-free survival, and a hazard ratio of 0.29 compared to the paclitaxel alone control," said
- Prev
- 1
- Next